Tocosol® paclitaxel -: Anticancer formulation

Paclitaxel is an important anticancer agent with a wide range of activity against solid tumors. However, the available paclitaxel-based anticancer formulations, such as Taxol(R), are associated with numerous drawbacks, including expensive and time-consuming drug preparation, long infusion periods and adverse side effects. Tocosol(R) Paclitaxel (S-8184), a Cremophor-free, vitamin E-based paclitaxel emulsion, has been designed to overcome the limitations associated with Taxol(R) - and generic paclitaxel-based chemotherapy. Tocosol(R) Paclitaxel is a ready-to-use formulation, and it allows a dose of paclitaxel to be administered to patients in 15 min instead of the 3 h required with Taxol(R). Preclinical and clinical results to date have shown that Tocosol(R) Paclitaxel has less toxicity and greater anticancer efficacy than Taxol(R). Tocosol(R) Paclitaxel is currently in phase III trials for the treatment of metastatic breast cancer.